Abstract Library

#4246 Prevalence of germline mutations in pancreatic neuroendocrine tumors

Introduction: Approximately 10% of pancreatic neuroendocrine tumors (PanNETs) develop due to inherited syndromes. However, generally genetic counseling and testing is not performed routinely and little accumulated on the prevalence of PanNETs associated with the presence of germline mutations.

Conference:

Presenting Author:

Authors: Salimgereeva D, Feidorov I, Konyakhina A,

Keywords: PanNET, GENOME, NGS, CHEK2, MEN1,

#4243 Role of gastric mucosa evaluation in diagnostic of pancreatic neuroendocrine tumors functional status

Introduction: Accessibility of high-precision imaging dramatically increased detection rate of small asymptomatic pancreatic neuroendocrine tumors (PanNETs). Functioning status is indication for surgical treatment with high perioperative risks, while increased level of NET markers could be associated with gastric mucosa atrophy or intake of proton pump inhibitors (PPI) and nor with tumor secretion.

Conference:

Presenting Author:

Authors: Salimgereeva D, Feidorov I, Konyakhina A,

Keywords: PanNET, chronic atrophic gastritis, marker, OLGA, anti-parietal cell antibodies,

#4209 Transcriptomic and spliceosomic landscapes of pancreatic neuroendocrine tumors generated through Oxford Nanopore Technology sequencing

Introduction: Pancreatic Neuroendocrine tumors (PanNETs) are rare neoplasms with heterogenous nature, still poorly understood. Their low mutational burden has prompted to explore other molecular aspects, from epigenomics to transcriptomics. Increasing evidence indicates that transcriptomic changes, often derived from alterations in alternative splicing, can generate isoforms with oncogenic potential. In this context, long-read Oxford Nanopore Technology (ONT) has emerged as an ideal suited sequencing tool to deeply study transcriptomics and splicing variants.

Conference:

Presenting Author: Moreno Montilla M

Authors: Moreno Montilla M, Jones G, Jeffries A, Blazquez Encinas Rey R, Bamford R,

Keywords: Pancreatic Neuroendocrine Tumor, Oxford Nanopore Technology Sequencing, Transcriptomics, Splicing, Fusion Genes,

#4206 Specific spliceosomic landscapes reveal a possible link between RNA processing and panNETs behaviour

Introduction: Pancreatic Neuroendocrine Tumors (PanNETs) are characterized by a low number of mutations. Despite genomics, transcriptomics and epigenomics studies have helped to understand the molecular features of PanNETs, there is still a vast unexplored ground for better comprehension of this disease. In this context, we have previously documented that RNA splicing is dysregulated in these tumors, which unveils new avenues to discover potential biomarkers and therapeutic targets. However, clinical and molecular implications of this dysregulation are still very poorly understood.

Conference:

Presenting Author: Pedraza-Arévalo S

Authors: Pedraza-Arévalo S, Blázquez-Encinas R, García-Vioque V, Moreno-Montilla M, Ruiz-Palacios D,

Keywords: pancreatic neuroendocrine tumor, splicing, RNA, grade, metastasis,

#4157 Decoding and targeting of metabolic heterogeneity in pancreatic neuroendocrine tumors (PanNETs): MCT1 and MCT4 in the crosshair for precision therapy

Introduction: Mechanisms driving progression from indolent to aggressive and metastatic disease in PanNET are largely unknown. Recent transcriptome and epigenome analyses suggest a stepwise progression model leading to enhanced proliferation, de-differentiation, and metabolic reprogramming. However, the metabolic landscape at different stages and the therapeutic potential of targeting metabolic proteins remain largely uncharacterized.

Conference:

Presenting Author: Sadowski M

Authors: Bräutigam K, Straub J, Bihi A, Andreasi V, Kirchner P,

Keywords: metabolic heterogeneity, 3D model, precision medicine, metabolic subtype, PanNET, hypoxia, lactate efflux, microvessel density, MCT1/MCT4,